# NAVER D2SF joins $10M bridge for ImpriMed's AI precision medicine push

_Published Friday, September 18, 2026 at 11:19 PM EDT · Capital, AI · Latest · Tier 2 — Notable_

![NAVER's Venture Capital Arm Invests in U.S. AI Precision Medicine Startup ImpriMed — Primary](https://img.biggo.com/kLdZgbTTvQQIOAdZKtd6zQojK4D7jIXkBx4Brvq2UZI/fit/1200/0/sm/0/aHR0cHM6Ly9pbWcuYmdvLm9uZS9uZXdzLWltYWdlL2FpX2dlbmVyYXRlZC8yMDI2LTA5LzliMjI2YjdhLTFmYzgtNGRlMi1iZmY1LTFiMjM3MTkyYTJhM18xNzg5NzQ1Mzk1X2RlZmF1bHQuanBn.jpg)

NAVER's corporate venture arm D2SF participated in a $10 million Series A2 bridge for ImpriMed, a Silicon Valley AI precision medicine company, the investor said.

LB Investment led the round, joined by Samsung Securities and Alois Ventures, with BonAngels and Han River Partners increasing commitments. ImpriMed combines ex vivo analysis of live patient-derived cancer cells with genomic and clinical data to recommend treatments. It targets blood cancers and bloodstream infections, aiming for FDA clearance and CLIA certification by the first quarter of 2027, and cites Mayo Clinic among commercial partners.

The company says its models have accumulated more than 3.5 million data points.

## Sources

- [finance.biggo.com](https://finance.biggo.com/news/9b226b7a-1fc8-4de2-bff5-1b237192a2a3)

---
Canonical: https://techandbusiness.org/newswire/kZCzZGldqlbjCf65Ma7X-h
Published: 2026-09-19T03:19:48.350Z
Story chronology: 2026-09-18T15:25:24.000Z
Retrieved: 2026-09-19T05:24:39.070Z
Publisher: Tech & Business (techandbusiness.org)